🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria

RecruitingPhase 2, Phase 3Ages 18 Years - 75 YearsAllBeijing InnoCare Pharma Tech Co., Ltd.
NCT07378527 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The purpose of this study is to compare the efficacy and safety of ICP-332 in moderate to severe chronic spontaneous urticaria subjects inadequately controlled by second generation H1-antihistamines

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * 1\. Men and women aged 18 to 75 years. * 2\. Diagnosis of CSU inadequately controlled by second generation H1-antihistamines. * 3\. CSU duration for ≥ 6 months prior to randomization. * 4\. Before initiating any screening or study-specific procedures, the subject must voluntarily sign the informed consent form. Exclusion Criteria: * 1\. Having the other medical conditions related to CSU or other skin diseases/conditions. * 2\. Potential medical conditions or issues. * 3\. Pregnant female subjects or lactating female subjects. * 4\. The investigator determines that the subject is unsuitable for participating in this study for any reason.
💊

What it tests

  • ICP-332 Tablets
  • ICP-332 placebo Tablets
  • ICP-332 Tablets
📍

Where

30 sites
Bengbu Medical University First Affiliated Hospital
Bengbu, China
The Second Affiliated Hospital of Wannan Medical College
Wuhu, China
Peking University People's Hospital
Beijing, China
Beijing Tongren Hospital, Capital Medical University
Beijing, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China
Chongqing Traditional Chinese Medicine Hospital
Chongqing, China
First Affiliated Hospital of Fujian Medical University
Fuzhou, China
Dermatology Hospital of Southern Medical University
Guangzhou, China

…and 22 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy